Art. -Nr.: HY-12723

Apomorphine

(Synonyms: (-)-Apomorphine)

3 Cited Publications

Kundenbewertung

Based on 3 publication(s) in Google Scholar

Apomorphine ((-)-Apomorphine) is a potent dopamine receptor agonist. Apomorphine also inhibit MAO-A and MAO-B. Apomorphine exerts neuroprotective effect and can relax rat corpus cavernosum. Apomorphine can inhibit ROS production, DNA fragmentation and inibit JNK and ERK1/2 phosphorylation. Apomorphine can enhance degradation of intracellular Aβ40 and Aβ42, reduces tau protein levels and inhibit MMP-9 expression. Apomorphine is a highly potent radical scavenger and iron chelator. Apomorphine can be used for the researches of dementia, parkinson's disease, alzheimer disease, breast carcinoma, and erectile dysfunction.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.19%
CAS. Nr.: 58-00-4
Formel: C₁₇H₁₇NO₂
Molecular Weight:267.32

Speicherung:

-20°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Apomorphine Chemical Structure

CAS. Nr.: 58-00-4

Größe

Preis

Verfügbarkeit

Menge

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Angebot einholen Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Angebot einholen Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Massenanfrage

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (3)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

MAO-A

MAO-B

ERK1

ERK2

MMP-9

Alle Dopamine Receptor Isoform-spezifische Produkte anzeigen :

Alle Monoamine Oxidase Isoform-spezifische Produkte anzeigen :

MAO-A
MAO-B

Alle JNK Isoform-spezifische Produkte anzeigen :

Alle ERK Isoform-spezifische Produkte anzeigen :

Alle MMP Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
Astrocyte	EC₅₀	10.19 μM Compound: 6	Antiproliferative activity against mouse astrocyte cells by MTT assay Antiproliferative activity against mouse astrocyte cells by MTT assay	[PMID: 17417631]
CHO	EC₅₀	4 nM Compound: 19, apomorphine	Agonist activity at human dopamine D2 receptor expressed in CHO cells assessed as inhibition of forskolin-stimulated cAMP production Agonist activity at human dopamine D2 receptor expressed in CHO cells assessed as inhibition of forskolin-stimulated cAMP production	[PMID: 18313303]
CHO	EC₅₀	52 nM Compound: 19, apomorphine	Agonist activity at human recombinant dopamine D1 receptor expressed in CHO cells assessed as stimulation of cAMP production Agonist activity at human recombinant dopamine D1 receptor expressed in CHO cells assessed as stimulation of cAMP production	[PMID: 18313303]
CHO	EC₅₀	7 nM Compound: apomorphine	Agonist activity at human recombinant dopamine D3 receptor expressed in CHO cells assessed as inhibition of forskolin-stimulated cAMP accumulation Agonist activity at human recombinant dopamine D3 receptor expressed in CHO cells assessed as inhibition of forskolin-stimulated cAMP accumulation	[PMID: 17976986]
CHO-K1	EC₅₀	30 nM Compound: 1	Agonist activity at rat D2 dopamine receptor expressed in CHOK1 cells assessed as [35S]GTPgammaS binding after 90 mins by liquid scintillation counter Agonist activity at rat D2 dopamine receptor expressed in CHOK1 cells assessed as [35S]GTPgammaS binding after 90 mins by liquid scintillation counter	[PMID: 21550699]
CHO-K1	EC₅₀	53 nM Compound: 1	Agonist activity at rat dopamine D2short receptor expressed in CHO-K1 cells assessed as stimulation of [35S]GTPgammaS binding by liquid scintillation counting Agonist activity at rat dopamine D2short receptor expressed in CHO-K1 cells assessed as stimulation of [35S]GTPgammaS binding by liquid scintillation counting	[PMID: 19454369]
CHO-K1	IC₅₀	4.2 nM Compound: Apomorphine	Agonist activity at human dopamine D2 receptor expressed in CHOK1 cells assessed as calcium mobilization by radiometric and luminescence plate counting method Agonist activity at human dopamine D2 receptor expressed in CHOK1 cells assessed as calcium mobilization by radiometric and luminescence plate counting method	[PMID: 25557493]
COS-7	IC₅₀	118 nM Compound: Apomorphine	Displacement of [3H]nemonapride from Rattus norvegicus (rat) wild type dopamine D2 receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting Displacement of [3H]nemonapride from Rattus norvegicus (rat) wild type dopamine D2 receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting	10.1007/s00044-004-0006-x
COS-7	IC₅₀	135 nM Compound: Apomorphine	Displacement of [3H]nemonapride from Rattus norvegicus (rat) chimeric dopamine D2 trunk/D2 tail receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting Displacement of [3H]nemonapride from Rattus norvegicus (rat) chimeric dopamine D2 trunk/D2 tail receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting	10.1007/s00044-004-0006-x
COS-7	IC₅₀	24.3 nM Compound: Apomorphine	Displacement of [3H]nemonapride from Rattus norvegicus (rat) chimeric dopamine D3 trunk/D2 tail receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting Displacement of [3H]nemonapride from Rattus norvegicus (rat) chimeric dopamine D3 trunk/D2 tail receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting	10.1007/s00044-004-0006-x
COS-7	IC₅₀	27.2 nM Compound: Apomorphine	Displacement of [3H]nemonapride from Rattus norvegicus (rat) chimeric dopamine D3 trunk/D3 tail receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting Displacement of [3H]nemonapride from Rattus norvegicus (rat) chimeric dopamine D3 trunk/D3 tail receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting	10.1007/s00044-004-0006-x
COS-7	IC₅₀	29.4 nM Compound: Apomorphine	Displacement of [3H]nemonapride from Rattus norvegicus (rat) wild type dopamine D3 receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting Displacement of [3H]nemonapride from Rattus norvegicus (rat) wild type dopamine D3 receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting	10.1007/s00044-004-0006-x
COS-7	IC₅₀	69.5 nM Compound: Apomorphine	Displacement of [3H]nemonapride from Rattus norvegicus (rat) chimeric dopamine D2 trunk/D3 tail receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting Displacement of [3H]nemonapride from Rattus norvegicus (rat) chimeric dopamine D2 trunk/D3 tail receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting	10.1007/s00044-004-0006-x
HEK293	EC₅₀	0.4 nM Compound: Apomorphine	In vitro effective concentration tested on HEK293 cells co-transfected with rat Dopamine receptor D2 using FLIPR assay In vitro effective concentration tested on HEK293 cells co-transfected with rat Dopamine receptor D2 using FLIPR assay	[PMID: 15239663]
HEK293	EC₅₀	0.4 nM Compound: Apomorphine	Agonist activity at rat D2 receptor in HEK293 cells coexpressing G-alpha-qo5 by FLIPR Agonist activity at rat D2 receptor in HEK293 cells coexpressing G-alpha-qo5 by FLIPR	[PMID: 17149874]
HEK293	EC₅₀	1.5 nM Compound: Apomorphine	In vitro effective concentration tested on HEK293 cells co-transfected with ferret Dopamine receptor D4 using FLIPR assay In vitro effective concentration tested on HEK293 cells co-transfected with ferret Dopamine receptor D4 using FLIPR assay	[PMID: 15239663]
HEK293	EC₅₀	1.5 nM Compound: Apomorphine	Agonist activity at ferret D4 receptor in HEK293 cells coexpressing G-alpha-qo5 by FLIPR Agonist activity at ferret D4 receptor in HEK293 cells coexpressing G-alpha-qo5 by FLIPR	[PMID: 17149874]
HEK293	EC₅₀	1.8 nM Compound: Apomorphine	In vitro effective concentration tested on HEK293 cells co-transfected with ferret Dopamine receptor D2 using FLIPR assay In vitro effective concentration tested on HEK293 cells co-transfected with ferret Dopamine receptor D2 using FLIPR assay	[PMID: 15239663]
HEK293	EC₅₀	1.8 nM Compound: Apomorphine	Agonist activity at ferret D2 receptor in HEK293 cells coexpressing Galphaqo5 by FLIPR Agonist activity at ferret D2 receptor in HEK293 cells coexpressing Galphaqo5 by FLIPR	[PMID: 17149874]
HEK293	EC₅₀	25.7 nM Compound: 1	Agonist activity at human dopamine D1 receptor expressed in HEK293 cells assessed as cAMP accumulation after 15 mins Agonist activity at human dopamine D1 receptor expressed in HEK293 cells assessed as cAMP accumulation after 15 mins	[PMID: 23727194]
HEK293	EC₅₀	4 nM Compound: 1	Agonist activity at human dopamine D2L receptor expressed in HEK293 cells assessed as forskolin-stimulated cAMP accumulation after 15 mins Agonist activity at human dopamine D2L receptor expressed in HEK293 cells assessed as forskolin-stimulated cAMP accumulation after 15 mins	[PMID: 23727194]
HEK293	EC₅₀	4.3 nM Compound: Apomorphine	In vitro effective concentration tested on HEK293 cells co-transfected with human Dopamine receptor D4 using FLIPR assay In vitro effective concentration tested on HEK293 cells co-transfected with human Dopamine receptor D4 using FLIPR assay	[PMID: 15239663]
HEK293	EC₅₀	4.3 nM Compound: Apomorphine	Agonist activity at human D4.4 receptor in HEK293 cells coexpressing G-alpha-qo5 by FLIPR Agonist activity at human D4.4 receptor in HEK293 cells coexpressing G-alpha-qo5 by FLIPR	[PMID: 17149874]
HEK293	EC₅₀	5.5 nM Compound: Apomorphine	In vitro effective concentration tested on HEK293 cells co-transfected with rat Dopamine receptor D4 using FLIPR assay In vitro effective concentration tested on HEK293 cells co-transfected with rat Dopamine receptor D4 using FLIPR assay	[PMID: 15239663]
HEK293	EC₅₀	5.5 nM Compound: Apomorphine	Agonist activity at rat D4 receptor in HEK293 cells coexpressing G-alpha-qo5 by FLIPR Agonist activity at rat D4 receptor in HEK293 cells coexpressing G-alpha-qo5 by FLIPR	[PMID: 17149874]
HEK293	EC₅₀	5.8 nM Compound: Apomorphine	In vitro effective concentration tested on HEK293 cells co-transfected with human Dopamine receptor D2 using FLIPR assay In vitro effective concentration tested on HEK293 cells co-transfected with human Dopamine receptor D2 using FLIPR assay	[PMID: 15239663]
HEK293	EC₅₀	5.8 nM Compound: Apomorphine	Agonist activity at human D2 receptor in HEK293 cells coexpressing G-alpha-qo5 by FLIPR Agonist activity at human D2 receptor in HEK293 cells coexpressing G-alpha-qo5 by FLIPR	[PMID: 17149874]
HEK293	IC₅₀	20.8 μM Compound: apomorphine	Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells by confocal microscopy Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells by confocal microscopy	[PMID: 18788725]
Medulloblastoma cell	EC₅₀	0.168 μM Compound: 6	Antiproliferative activity against mouse medulloblastoma cells harboring heterozygous ptch1 gene by MTT assay Antiproliferative activity against mouse medulloblastoma cells harboring heterozygous ptch1 gene by MTT assay	[PMID: 17417631]
Pituitary gland cell	EC₅₀	20 nM Compound: apomorphine	Agonist activity at human recombinant dopamine D2 receptor expressed in rat pituitary cells assessed as inhibition of forskolin-stimulated cAMP accumulation Agonist activity at human recombinant dopamine D2 receptor expressed in rat pituitary cells assessed as inhibition of forskolin-stimulated cAMP accumulation	[PMID: 17976986]

In Vitro

Apomorphine (0-250 μM; 30 min) inhibits striatal MAO-A and MAO-B activities from C57BL mice with IC₅₀ values of 93 μM and 241 μM, respectively^[2].
Apomorphine is a highly potent radical scavenger and iron chelator with an IC₅₀ of 0.2-0.5 μM^[2].
Apomorphine (7.5-15 μM; 24 h) protects SH-SY5Y cells against 6-OHDA (HY-B1081)-induced cell death, ROS production and DNA fragmentation^[3].
Apomorphine (15 μM; 8-24 h) attenuates 6-OHDA-induced JNK phosphorylation in SH-SY5Y cells^[3].
Apomorphine (7.5-30 μM; 24 h) does not induce intracellular glutathione synthesis in SH-SY5Y cells^[3].
Apomorphine (10 μM; 2 h pre-incubation) significantly enhances degradation of intracellular Aβ40 and Aβ42 in SH-SY5Y cells, reversing MG132 (HY-13259)-mediated inhibition of Aβ breakdown^[4].
Apomorphine (2-10 μM) significantly increases intracellular 20S proteasome and IDE activity in SH-SY5Y cells, and partially reverses MG132-induced proteasome inhibition^[4].
Apomorphine (5-20 μM; 24 h) significantly protects SH-SY5Y cells from H₂O₂-induced cell death and reduces H₂O₂-mediated p53 protein elevation^[4].
Apomorphine (10-100 μM; 24 h) exhibits minimal cytotoxicity in MCF-7 human breast carcinoma cells at concentrations ≤25 μM, with a 25% reduction in cell viability observed at 50 μM^[5].
Apomorphine (10-40 μM; 24 h) potently inhibits TNF-α- and PMA (HY-18739)-induced MMP-9 secretion in MCF-7 human breast carcinoma cells without altering MMP-2 levels^[5].
Apomorphine (40 μM; 24 h) inhibits TNF-α-induced invasion by MCF-7 human breast carcinoma cells by 80%^[5].
Apomorphine (20-40 μM; 18 h) suppresses TNF-α-induced MMP-9 mRNA expression in MCF-7 human breast carcinoma cells^[5].
Apomorphine (10-40 μM; 6 h) suppresses TNF-α-induced nuclear translocation of the AP-1 subunit c-Jun in MCF-7 human breast carcinoma cells without altering NF-κB subunit p65 nuclear translocation^[5].
Apomorphine (10-40 μM; 15-30 min) and (40 μM; 15, 30 min) inhibits TNF-α-induced phosphorylation of ERK1/2 in MCF-7 human breast carcinoma cells without altering phosphorylation of JNK, p38, or Akt^[5].
Apomorphine (10⁻⁹-10⁻⁴ M) produces concentration-dependent relaxation of rat corpus cavernosum^[6].
Apomorphine (100 μM; 4 min) does not alter tissue cGMP or cAMP levels in Phenylephrine (HY-B0769)-precontracted isolated rat corpus cavernosum strips^[6].
Apomorphine (0-600 μM) induces C6 cells (EC₅₀ = 200 μM) and rat neuron death^[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[4]

Cell Line:

human neuroblastoma SH-SY5Y cells
Concentration:

5, 10 and 20 μM
Incubation Time:

24 h
Result:

Protected cells from H₂O₂-induced toxicity, with 10 μM being the most effective concentration.
Attenuated the H₂O₂-induced elevation of p53 protein levels.

RT-PCR^[5]

Cell Line:

MCF-7 human breast carcinoma cells
Concentration:

10, 20, 40 μM
Incubation Time:

18 h
Result:

Decreased TNF-α-induced MMP-9 mRNA expression at 20 and 40 μM.
Showed no effect on TNF-α-induced MMP-9 mRNA expression at 10 μM.

Western Blot Analysis^[5]

Cell Line:

MCF-7 human breast carcinoma cells
Concentration:

10, 20, 40 μM
Incubation Time:

15, 30 min, 6 h
Result:

Suppressed TNF-α-induced nuclear translocation of the AP-1 subunit c-Jun.
Left NF-κB subunit p65 nuclear translocation unaffected.
Inhibited TNF-α-induced phosphorylation of ERK1/2 for 15 min.
Reduced TNF-α-induced ERK1/2 phosphorylation at 15 and 30 min.

In Vivo

Apomorphine (1.0 mg/kg; injection; daily; 6 days) significantly reverses Scopolamine (HY-N0296)-induced dementia-related memory impairment, oxidative stress, reduced AChE activity, and altered hippocampal biogenic amine levels in male Albino Wistar rats^[1].
Apomorphine (5-10 mg/kg; s.c.; daily; 5 days) protects against MPTP MPTP (HY-W114750)-induced dopaminergic neurotoxicity in male C57BL mice, with 10 mg/kg almost completely preventing striatal dopamine loss and maintaining tyrosine hydroxylase content at 66.1% of control^[2].
Apomorphine (5-10 mg/kg; s.c.; once weekly; 1 month) significantly improves short-term memory function and reduces intraneuronal Aβ, p-tau, p53, and HO-1 levels in 3xTg-AD mice^[4].
Apomorphine (10-1000 nmol; s.c.; single dose) produces erectile responses in awake rats^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Albino Wistar (male, 180-200g, scopolamine-induced)^[1]
Dosage:

1.0 mg/kg
Administration:

Injection; daily; 6 days
Result:

Reduced latency to locate the platform for learning acquisition, memory consolidation, and memory retention, and reversed memory impairment.
Increased number of cage crossings and reduced AChE activity.

Animal Model:

3xTg-AD (hemizygous; homozygous; 6-month-old); non-Tg (same genetic background; 6-month-old)^[4]
Dosage:

5 mg/kg; 10 mg/kg
Administration:

S.c.; once a week; 1 month
Result:

Reduced latency to reach the platform in Morris water maze and decreased latency to the platform location in MWM probe trials.
Increased crossing counts of the platform location and increased percentage of time spent in the target quadrant.
Eliminated intraneuronal Aβ immunoreactivity in hemizygous 3xTg-AD at 5 mg/kg.
Decreased hyperphosphorylated tau (p-tau) levels, p53 and heme oxygenase-1 (HO-1) protein levels.
Caused no significant memory function alteration in non-Tg mice at 5 mg/kg.

Chemical Information

CAS. Nr. 58-00-4
Appearance Solid
Molecular Weight 267.32
Formel C₁₇H₁₇NO₂
Color Blue to blue-green
SMILES

OC1=CC=C2C(C3=C4C(CCN(C)[C@]4([H])C2)=CC=C3)=C1O
Synonyms

(-)-Apomorphine
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

-20°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (3)

All In Vivo Efficacy Study

Sort by:

Journal Impact Factor

NPJ Parkinsons Dis

GDNF signaling modulation by Akkermansia muciniphila ameliorates constipation-depression comorbidity in Parkinson's disease. [Abstract]

2025 Nov 28;11(1):342. PMID: 41315295

Apomorphine purchased from MedChemExpress. Usage Cited in: NPJ Parkinsons Dis. 2025 Nov 28;11(1):342. [Abstract]

Movement track of PBS + Apomorphine (1 mg/kg, ip, single dose) and 6-OHDA + Apomorphine groups in the Apomorphine-induced mouse rotation test.
Funct Integr Genomics

Tet1-mediated activation of the Ampk signaling by Trpv1 DNA hydroxymethylation exerts neuroprotective effects in a rat model of Parkinson's disease. [Abstract]

2024 Sep 17;24(5):161. PMID: 39285026
Genes

Transcriptomic Analysis of Diabetic Erectile Dysfunction Rats After Red Blood Cell Exosome Treatment. [Abstract]

2025 Jun 29;16(7):768. PMID: 40725424

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 50 mg/mL (187.04 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.7408 mL

18.7042 mL

37.4083 mL

5 mM

0.7482 mL

3.7408 mL

7.4817 mL

10 mM

0.3741 mL

1.8704 mL

3.7408 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (9.35 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (9.35 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (289 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Ikram H, et al. Memory enhancing and neuroprotective effects of apomorphine in a rat model of dementia. Metab Brain Dis. 2024;39(6):1051-1063. [Content Brief]

[2]. Grünblatt E, et al. Apomorphine protects against MPTP-induced neurotoxicity in mice. Mov Disord. 1999;14(4):612-618. [Content Brief]

[3]. Hara H, et al. Apomorphine attenuates 6-hydroxydopamine-induced apoptotic cell death in SH-SY5Y cells. Redox Rep. 2003;8(4):193-197. [Content Brief]

[4]. Himeno E, et al. Apomorphine treatment in Alzheimer mice promoting amyloid-β degradation. Ann Neurol. 2011;69(2):248-256. [Content Brief]

[5]. Jung YS, et al. Apomorphine suppresses TNF-α-induced MMP-9 expression and cell invasion through inhibition of ERK/AP-1 signaling pathway in MCF-7 cells. Biochem Biophys Res Commun. 2017;487(4):903-909. [Content Brief]

[6]. Matsumoto K, et al. Effects in vitro and in vivo by apomorphine in the rat corpus cavernosum. Br J Pharmacol. 2005;146(2):259-267. [Content Brief]

[7]. dos Santos El-Bachá R, et al. Toxic effects of apomorphine on rat cultured neurons and glial C6 cells, and protection with antioxidants. Biochem Pharmacol. 2001;61(1):73-85. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.7408 mL	18.7042 mL	37.4083 mL	93.5209 mL
	5 mM	0.7482 mL	3.7408 mL	7.4817 mL	18.7042 mL
	10 mM	0.3741 mL	1.8704 mL	3.7408 mL	9.3521 mL
	15 mM	0.2494 mL	1.2469 mL	2.4939 mL	6.2347 mL
	20 mM	0.1870 mL	0.9352 mL	1.8704 mL	4.6760 mL
	25 mM	0.1496 mL	0.7482 mL	1.4963 mL	3.7408 mL
	30 mM	0.1247 mL	0.6235 mL	1.2469 mL	3.1174 mL
	40 mM	0.0935 mL	0.4676 mL	0.9352 mL	2.3380 mL
	50 mM	0.0748 mL	0.3741 mL	0.7482 mL	1.8704 mL
	60 mM	0.0623 mL	0.3117 mL	0.6235 mL	1.5587 mL
	80 mM	0.0468 mL	0.2338 mL	0.4676 mL	1.1690 mL
	100 mM	0.0374 mL	0.1870 mL	0.3741 mL	0.9352 mL

Apomorphine

3 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Apomorphine

Publications Citing Use of MedChemExpress (MCE) Apomorphine

Alle Dopamine Receptor Isoform-spezifische Produkte anzeigen

Alle Monoamine Oxidase Isoform-spezifische Produkte anzeigen

Alle JNK Isoform-spezifische Produkte anzeigen

Alle ERK Isoform-spezifische Produkte anzeigen

Alle MMP Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (3)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Apomorphine Related Classifications

Art. -Nr.: HY-12723